Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

This activity was originally broadcast in conjunction with AMCP 2024.

Program Description

In individuals with relapsed/refractory multiple myeloma (MM) who required several prior treatments, bispecific antibodies (BsAbs) and other T-cell–directed therapies have demonstrated improved efficacy. Managed care professionals will be tasked with introducing these targeted agents and establishing treatment sequencing strategies within the existing framework of therapeutic options in MM. With improved understanding of the clinical impact of emerging BsAbs and chimeric antigen receptor (CAR) T-cell products, managed care professionals can develop clinical eligibility criteria and direct coverage issues for these therapies within the MM therapeutic landscape. Evidence will be presented regarding advantages and risks associated with these therapies at the clinical stage, as well as the need for strategies to continue to refine these treatments to make them more accessible. This program will examine available real-world data of the toxicity profiles of BsAbs and CAR T-cell therapies, duration of response, and other factors used to differentiate treatment selection between these immunotherapeutic agents to support optimal patient outcomes in relapsed/refractory MM.

Target audience: Managed care and oncology pharmacists

Type of activity: Application
Release date: May 3, 2024
Expiration date: May 3, 2025

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the patient- and disease-specific factors that drive treatment decisions for the use of novel immunotherapies in multiple myeloma (MM).
• Examine the therapeutic landscape and the guideline-recommended use of bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory MM.
• Analyze the recent safety and efficacy data from clinical trials of BsAbs and CAR T-cell therapies in the context of appropriate sequencing in the current MM care paradigms.
• Explore best practices and operational strategies to optimize health care resource utilization, safety, and patient outcomes when using novel immunotherapies in the treatment of relapsed/refractory MM.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-121-H01-P. The activity is available for CE credit through May 3, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Tyler Sandahl, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant: Advisory board member for Janssen

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following financial relationships with commercial interests to disclose:

Consultant: Omeros, SeaGen, Sanofi, BMS, KITE, AstraZeneca (advisory board participation)

Speaker: Omeros

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Daphne Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:

Former employee: GSK

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms